4.4 Review

Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer

Ina Valeria Zurlo et al.

Summary: The study found that pre-treatment NLR, TILs, and PD-L1 expression are correlated with the response to neoadjuvant chemotherapy and prognosis in LAGC patients, suggesting their significance in selecting patients for chemotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Article Oncology

Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach

Muxing Kang et al.

Summary: This study evaluated the molecular characteristics of hepatoid adenocarcinoma of the stomach (HAS) and found that it can be mainly categorized into genomic stable and chromosomal instability phenotypes, with wild type P53 status predicting better prognosis. The presence of tumor infiltrating lymphocytes suggested that some HAS patients may be suitable candidates for immune checkpoint blockade therapy. The immune prognostic index and derived neutrophil to lymphocyte ratio showed potential as reliable indicators for predicting prognosis of HAS.

TRANSLATIONAL ONCOLOGY (2022)

Review Oncology

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Deborah Blythe Doroshow et al.

Summary: PD-L1 expression is currently the best predictor of responsiveness to immune-checkpoint inhibitors, despite challenges in clinical use such as variability in different assays and cut-off points, as well as the lack of prospective comparisons with clinical outcomes. Nevertheless, several immunohistochemical assays have been approved for clinical use, with implications for pathology services and potential impacts on clinical outcomes. Comparison of FDA-approved PD-L1 assays, understanding of the varying implications of PD-L1 expression across different tumour types, and exploration of novel approaches to optimize its clinical utility are important topics for further research and practice.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Review Oncology

PD-1 and PD-L1 inhibitors in oesophago-gastric cancers

Tugba Akin Telli et al.

CANCER LETTERS (2020)

Article Pathology

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features

Xiaoqiao Liu et al.

PATHOLOGY RESEARCH AND PRACTICE (2020)

Article Medicine, Research & Experimental

Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer

Rong Yan et al.

MEDICAL SCIENCE MONITOR (2019)

Article Oncology

Cancer statistics, 2019

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

Review Biotechnology & Applied Microbiology

PD-L1 expression in human cancers and its association with clinical outcomes

Xin Wang et al.

ONCOTARGETS AND THERAPY (2016)

Article Multidisciplinary Sciences

Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease

Valentina Cappello et al.

SCIENTIFIC REPORTS (2016)

Article Gastroenterology & Hepatology

Pathology of Gastric Cancer and Its Precursor Lesions

Evgeny Yakirevich et al.

GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2013)

Review Oncology

The immune contexture in human tumours: impact on clinical outcome

Wolf Herman Fridman et al.

NATURE REVIEWS CANCER (2012)

Article Oncology

Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

Sahar M. A. Mahmoud et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Oncology

Immune Regulation of Cancer

Mary L. Disis

JOURNAL OF CLINICAL ONCOLOGY (2010)

Review Biochemistry & Molecular Biology

Immune infiltration in human tumors: a prognostic factor that should not be ignored

F. Pages et al.

ONCOGENE (2010)

Review Medicine, General & Internal

Evaluation of the quality of prognosis studies in systematic reviews

JA Hayden et al.

ANNALS OF INTERNAL MEDICINE (2006)

Article Mathematical & Computational Biology

Quantifying heterogeneity in a meta-analysis

JPT Higgins et al.

STATISTICS IN MEDICINE (2002)